Skip to main content
SpringerLink
Log in

Dual Disorders: Addiction and Other Mental Disorders. Integrating Mental Health

  • Chapter
  • First Online:
Advances in Psychiatry

Abstract

Understanding dual disorders (DDs) implies recognizing that an addiction is a mental illness and therefore a brain disease. There are common brain areas involved in both addictions and other mental illnesses; it could explain the high comorbidity between drug use and other psychiatric disorders. Factors increasing the vulnerability to develop an addiction include family history, early initiation of substance use, socially stressful environments and suffering from a mental illness. In addition, lifetime diagnosis of any mental illness has been found to be associated with higher prevalence of transition from substance use to substance use disorder. Social influences are critical factors that promote experimentation or initiation which, combined with an individual vulnerability, may lead to a substance use disorder development. Historically, there has been an artificial separation between services treating addiction disorders and services treating other mental illnesses. The new paradigm of addiction, which indicates that DDs are a brain disease, highlights the need to reconsider this model.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 229.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374(4):363–71.

    Article  CAS  Google Scholar 

  2. Drake RE, Mueser KT, Brunette MF, McHugo GJ. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatr Rehabil J. 2004;27(4):360–74.

    Article  PubMed  Google Scholar 

  3. Banerjee S, Clancy C, Crome I. Co-existing problems of mental disorder and substance misuse (dual diagnosis). An information manual—2002. London: Royal College of Psychiatrists Research Unit; 2002.

    Google Scholar 

  4. Arias F, Szerman N, Vega P, Mesias B, Basurte I, Morant C, et al. Madrid study on the prevalence and characteristics of outpatients with dual pathology in community mental health and substance misuse services. Adicciones. 2013;25(2):118–27.

    Article  PubMed  Google Scholar 

  5. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23(7):455–68.

    Article  CAS  PubMed  Google Scholar 

  6. Morisano D, Babor TF, Robaina KA. Co-occurrence of substance use disorders with other psychiatric disorders: implications for treatment services. Nordic Stud Alcohol Drugs. 2014;31(1):5–25.

    Article  Google Scholar 

  7. Arias F, Szerman N, Vega P, Mesias B, Basurte I, Rentero D. Bipolar disorder and substance use disorders. Madrid study on the prevalence of dual disorders/pathology. Adicciones. 2016;29(3):186–94.

    Article  Google Scholar 

  8. Budney AJ. Are specific dependence criteria necessary for different substances: how can research on cannabis inform this issue? Addiction. 2006;101(Suppl 1):125–33.

    Article  PubMed  Google Scholar 

  9. Muthen B. Should substance use disorders be considered as categorical or dimensional? Addiction. 2006;101(Suppl 1):6–16.

    Article  PubMed  Google Scholar 

  10. Groman SM, Jentsch JD. Cognitive control and the dopamine D(2)-like receptor: a dimensional understanding of addiction. Depress Anxiety. 2012;29(4):295–306.

    Article  CAS  PubMed  Google Scholar 

  11. Baillie AJ, Teesson M. Continuous, categorical and mixture models of DSM-IV alcohol and cannabis use disorders in the Australian community. Addiction. 2010;105(7):1246–53.

    Article  PubMed  Google Scholar 

  12. Helzer JE, van den Brink W, Guth SE. Should there be both categorical and dimensional criteria for the substance use disorders in DSM-V? Addiction. 2006;101(Suppl 1):17–22.

    Article  PubMed  Google Scholar 

  13. Fraguas D, Diaz-Caneja CM, State MW, O'Donovan MC, Gur RE, Arango C. Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance. Psychol Med. 2016;23:1–5.

    Google Scholar 

  14. Compton WM, Dawson DA, Goldstein RB, Grant BF. Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol. Drug Alcohol Depend. 2013;132(1–2):387–90.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Grant BF, Goldstein RB, Chou SP, Huang B, Stinson FS, Dawson DA, et al. Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Mol Psychiatry. 2009;14(11):1051–66.

    Article  CAS  PubMed  Google Scholar 

  16. Pang RD, Farrahi L, Glazier S, Sussman S, Leventhal AM. Depressive symptoms, negative urgency and substance use initiation in adolescents. Drug Alcohol Depend. 2014;144:225–30.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Blanco C, Alderson D, Ogburn E, Grant BF, Nunes EV, Hatzenbuehler ML, et al. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991–1992 and 2001–2002. Drug Alcohol Depend. 2007;90(2):252–60.

    Article  PubMed  Google Scholar 

  18. Dawson DA, Goldstein RB, Grant BF. Rates and correlates of relapse among individuals in remission from DSM-IV alcohol dependence: a 3-year follow-up. Alcohol Clin Exp Res. 2007;31(12):2036–45.

    Article  PubMed  Google Scholar 

  19. Blanco C, Alegria AA, Liu SM, Secades-Villa R, Sugaya L, Davies C, et al. Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2012;73(6):865–73.

    Article  PubMed  Google Scholar 

  20. Mann K, Fauth-Buhler M, Higuchi S, Potenza MN, Saunders JB. Pathological gambling: a behavioral addiction. World Psychiatry. 2016;15(3):297–8.

    Article  PubMed  Google Scholar 

  21. Potenza MN. Should addictive disorders include non-substance-related conditions? Addiction. 2006;101(Suppl 1):142–51.

    Article  PubMed  Google Scholar 

  22. Shaffer HJ. Strange bedfellows: a critical view of pathological gambling and addiction. Addiction. 1999;94(10):1445–8.

    Article  CAS  PubMed  Google Scholar 

  23. Kraus SW, Voon V, Kor A, Potenza MN. Searching for clarity in muddy water: future considerations for classifying compulsive sexual behavior as an addiction. Addiction. 2016;111(12):2113–4.

    Article  PubMed  Google Scholar 

  24. Kraus SW, Voon V, Potenza MN. Should compulsive sexual behavior be considered an addiction? Addiction. 2016;111(12):2097–106.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Crockford D, Quickfall J, Currie S, Furtado S, Suchowersky O, El-Guebaly N. Prevalence of problem and pathological gambling in Parkinson's disease. J Gambl Stud. 2008;24(4):411–22.

    Article  PubMed  Google Scholar 

  26. el-Guebaly N, Mudry T, Zohar J, Tavares H, Potenza MN. Compulsive features in behavioural addictions: the case of pathological gambling. Addiction. 2012;107(10):1726–34.

    Article  PubMed  Google Scholar 

  27. Potenza MN. Commentary on: are we overpathologizing everyday life? A tenable blueprint for behavioral addiction research. Defining and classifying non-substance or behavioral addictions. J Behav Addict. 2015;4(3):139–41.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Gearhardt AN, Grilo CM, DiLeone RJ, Brownell KD, Potenza MN. Can food be addictive? Public health and policy implications. Addiction. 2011;106(7):1208–12.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Szerman N, Vega P, Grau-Lopez L, Barral C, Basurte-Villamor I, Mesias B, et al. Dual diagnosis resource needs in Spain: a national survey of professionals. J Dual Diagn. 2014;10(2):84–90.

    Article  PubMed  Google Scholar 

  30. Volkow N. Comorbidity: addiction and other mental illnesses. Bethesda: National Institute on Drug Abuse; 2009.

    Google Scholar 

  31. Drake RE, Green AI. A call for creativity in dual diagnosis research. J Dual Diagn. 2015;11(2):93–6.

    Article  PubMed  Google Scholar 

  32. Stanis JJ, Andersen SL. Reducing substance use during adolescence: a translational framework for prevention. Psychopharmacology. 2014;231(8):1437–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Simon N, Belzeaux R, Adida M, Azorin JM. Negative symptoms in schizophrenia and substance-related disorders. L'Encéphale. 2015;41(6 Suppl 1):6S27–31.

    Article  CAS  PubMed  Google Scholar 

  34. Wilens TE, Martelon M, Joshi G, Bateman C, Fried R, Petty C, et al. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry. 2011;50(6):543–53.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lev-Ran S, Imtiaz S, Rehm J, Le Foll B. Exploring the association between lifetime prevalence of mental illness and transition from substance use to substance use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). Am J Addict. 2013;22(2):93–8.

    Article  PubMed  Google Scholar 

  36. Wilens TE, Adamson J, Monuteaux MC, Faraone SV, Schillinger M, Westerberg D, et al. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008;162(10):916–21.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Griffin KW, Botvin GJ. Evidence-based interventions for preventing substance use disorders in adolescents. Child Adolesc Psychiatr Clin N Am. 2010;19(3):505–26.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Drake RE, Essock SM, Shaner A, Carey KB, Minkoff K, Kola L, et al. Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv. 2001;52(4):469–76.

    Article  CAS  PubMed  Google Scholar 

  39. Lipari RN, Hedden SL, Hughes A. Substance use and mental health estimates from the 2013 National Survey on Drug Use and Health: Overview of findings. The CBHSQ Report. Rockville: Substance Abuse and Mental Health Services Administration; 2013.

    Google Scholar 

  40. Narrow WE, Regier DA, Rae DS, Manderscheid RW, Locke BZ. Use of services by persons with mental and addictive disorders. Findings from the National Institute of Mental Health Epidemiologic Catchment Area Program. Arch Gen Psychiatry. 1993;50(2):95–107.

    Article  CAS  PubMed  Google Scholar 

  41. Kessler RC, Avenevoli S, McLaughlin KA, Green JG, Lakoma MD, Petukhova M, et al. Lifetime co-morbidity of DSM-IV disorders in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A). Psychol Med. 2012;42(9):1997–2010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58(8):668–76.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Miquel L, Roncero C, Lopez-Ortiz C, Casas M. Epidemiological and diagnostic axis I gender differences in dual diagnosis patients. Adicciones. 2011;23(2):165–72.

    Article  PubMed  Google Scholar 

  44. Compton WM, Dawson DA, Conway KP, Brodsky M, Grant BF. Transitions in illicit drug use status over 3 years: a prospective analysis of a general population sample. Am J Psychiatry. 2013;170(6):660–70.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol. 2007;64(11):1575–9.

    Article  PubMed  Google Scholar 

  46. Mendelsohn CP, Kirby DP, Castle DJ. Smoking and mental illness. An update for psychiatrists. Australas Psychiatry. 2015;23(1):37–43.

    Article  PubMed  Google Scholar 

  47. Sheals K, Tombor I, McNeill A, Shahab L. A mixed-method systematic review and meta-analysis of mental health professionals’ attitudes toward smoking and smoking cessation among people with mental illnesses. Addiction. 2016;111(9):1536–53.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195–204.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;72(12):1235–42.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Yuodelis-Flores C, Ries RK. Addiction and suicide: a review. Am J Addict. 2015;24(2):98–104.

    Article  PubMed  Google Scholar 

  51. Borges G, Loera CR. Alcohol and drug use in suicidal behaviour. Curr Opin Psychiatry. 2010;23(3):195–204.

    Article  PubMed  Google Scholar 

  52. Borges G, Walters EE, Kessler RC. Associations of substance use, abuse, and dependence with subsequent suicidal behavior. Am J Epidemiol. 2000;151(8):781–9.

    Article  CAS  PubMed  Google Scholar 

  53. Conner KR, Pinquart M, Gamble SA. Meta-analysis of depression and substance use among individuals with alcohol use disorders. J Subst Abus Treat. 2009;37(2):127–37.

    Article  Google Scholar 

  54. Conner KR, Gamble SA, Bagge CL, He H, Swogger MT, Watts A, et al. Substance-induced depression and independent depression in proximal risk for suicidal behavior. J Stud Alcohol Drugs. 2014;75(4):567–72.

    Article  PubMed  Google Scholar 

  55. Conner KR, Duberstein PR. Predisposing and precipitating factors for suicide among alcoholics: empirical review and conceptual integration. Alcohol Clin Exp Res. 2004;28(5 Suppl):6S–17S.

    Article  PubMed  Google Scholar 

  56. Gonzalez VM, Bradizza CM, Collins RL. Drinking to cope as a statistical mediator in the relationship between suicidal ideation and alcohol outcomes among underage college drinkers. Psychol Addict Behav. 2009;23(3):443–51.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Szerman N, Martinez-Raga J, Peris L, Roncero C, Basurte I, Vega P, et al. Rethinking dual disorders/pathology. Addict Disord Their Treat. 2013;12(1):1–10.

    Article  Google Scholar 

  58. Verdejo-Garcia A, Bechara A. A somatic marker theory of addiction. Neuropharmacology. 2009;56(Suppl 1):48–62.

    Article  CAS  PubMed  Google Scholar 

  59. Garcia-Garcia I, Horstmann A, Jurado MA, Garolera M, Chaudhry SJ, Margulies DS, et al. Reward processing in obesity, substance addiction and non-substance addiction. Obes Rev. 2014;15(11):853–69.

    Article  CAS  PubMed  Google Scholar 

  60. Wilcox CE, Pommy JM, Adinoff B. Neural circuitry of impaired emotion regulation in substance use disorders. Am J Psychiatry. 2016;173(4):344–61.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–38.

    Article  PubMed  Google Scholar 

  62. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36(2):241–63.

    Article  CAS  PubMed  Google Scholar 

  63. Hyatt CJ, Assaf M, Muska CE, Rosen RI, Thomas AD, Johnson MR, et al. Reward-related dorsal striatal activity differences between former and current cocaine dependent individuals during an interactive competitive game. PLoS One. 2012;7(5):e34917.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Olsen VV, Lugo RG, Sutterlin S. The somatic marker theory in the context of addiction: contributions to understanding development and maintenance. Psychol Res Behav Manag. 2015;8:187–200.

    PubMed  PubMed Central  Google Scholar 

  65. Arias F, Szerman N, Vega P, Mesias B, Basurte I, Morant C, et al. Abuse or dependence on cannabis and other psychiatric disorders. Madrid study on dual pathology prevalence. Actas Esp Psiquiatr. 2013;41(2):122–9.

    PubMed  Google Scholar 

  66. Wang Y, Zhu J, Li Q, Li W, Wu N, Zheng Y, et al. Altered fronto-striatal and fronto-cerebellar circuits in heroin-dependent individuals: a resting-state FMRI study. PLoS One. 2013;8(3):e58098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Durrant R, Adamson S, Todd F, Sellman D. Drug use and addiction: evolutionary perspective. Aust N Z J Psychiatry. 2009;43(11):1049–56.

    Article  PubMed  Google Scholar 

  68. Volkow ND, Koob G. Brain disease model of addiction: why is it so controversial? Lancet Psychiatry. 2015;2(8):677–9.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Szerman N, Lopez-Castroman J, Arias F, Morant C, Babin F, Mesias B, et al. Dual diagnosis and suicide risk in a Spanish outpatient sample. Subst Use Misuse. 2012;47(4):383–9.

    Article  PubMed  Google Scholar 

  70. van der Pol P, Liebregts N, de Graaf R, Ten Have M, Korf DJ, van den Brink W, et al. Mental health differences between frequent cannabis users with and without dependence and the general population. Addiction. 2013;108(8):1459–69.

    Article  PubMed  Google Scholar 

  71. Leyton M, Vezina P. Dopamine ups and downs in vulnerability to addictions: a neurodevelopmental model. Trends Pharmacol Sci. 2014;35(6):268–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Schlossarek S, Kempkensteffen J, Reimer J, Verthein U. Psychosocial determinants of cannabis dependence: a systematic review of the literature. Eur Addict Res. 2016;22(3):131–44.

    Article  PubMed  Google Scholar 

  73. Darke S, Torok M. The association of childhood physical abuse with the onset and extent of drug use among regular injecting drug users. Addiction. 2014;109(4):610–6.

    Article  PubMed  Google Scholar 

  74. Maniglio R. The role of child sexual abuse in the etiology of substance-related disorders. J Addict Dis. 2011;30(3):216–28.

    Article  PubMed  Google Scholar 

  75. Drake RE, Wallach MA, Alverson HS, Mueser KT. Psychosocial aspects of substance abuse by clients with severe mental illness. J Nerv Ment Dis. 2002;190(2):100–6.

    Article  PubMed  Google Scholar 

  76. Tsitsika A, Critselis E, Louizou A, Janikian M, Freskou A, Marangou E, et al. Determinants of internet addiction among adolescents: a case-control study. Sci World J. 2011;11:866–74.

    Article  Google Scholar 

  77. Wang PS, Angermeyer M, Borges G, Bruffaerts R, Tat Chiu W, De Girolamo G, et al. Delay and failure in treatment seeking after first onset of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry. 2007;6(3):177–85.

    PubMed  PubMed Central  Google Scholar 

  78. Bahorik AL, Newhill CE, Queen CC, Eack SM. Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychol Med. 2014;44(1):61–9.

    Article  CAS  PubMed  Google Scholar 

  79. Van Dorn RA, Desmarais SL, Swartz MS, Young MS, Sellers BG. Letter to the editor: critique of Bahorik et al. (2013)—‘Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors’. Psychol Med. 2014;44(3):668–70.

    Article  PubMed  Google Scholar 

  80. Desmarais SL, Van Dorn RA, Sellers BG, Young MS, Swartz MS. Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia. Psychol Addict Behav. 2013;27(3):774–87.

    Article  PubMed  Google Scholar 

  81. Van Dorn RA, Desmarais SL, Scott Young M, Sellers BG, Swartz MS. Assessing illicit drug use among adults with schizophrenia. Psychiatry Res. 2012;200(2–3):228–36.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Dragogna F, Mauri MC, Marotta G, Armao FT, Brambilla P, Altamura AC. Brain metabolism in substance-induced psychosis and schizophrenia: a preliminary PET study. Neuropsychobiology. 2014;70(4):195–202.

    Article  CAS  PubMed  Google Scholar 

  83. Daigre C, Roncero C, Grau-Lopez L, Martinez-Luna N, Prat G, Valero S, et al. Attention deficit hyperactivity disorder in cocaine-dependent adults: a psychiatric comorbidity analysis. Am J Addict. 2013;22(5):466–73.

    Article  PubMed  Google Scholar 

  84. Ozomaro U, Wahlestedt C, Nemeroff CB. Personalized medicine in psychiatry: problems and promises. BMC Med. 2013;11:132.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Muller-Spahn F. Individualized preventive psychiatry: syndrome and vulnerability diagnostics. Eur Arch Psychiatry Clin Neurosci. 2008;258(Suppl 5):92–7.

    Article  PubMed  Google Scholar 

  86. Williams LM. Defining biotypes for depression and anxiety based on large-scale circuit dysfunction: a theoretical review of the evidence and future directions for clinical translation. Depress Anxiety. 2016;34(1):9–24.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Mestre-Pinto JI, Domingo-Salvany A, Martin-Santos R, Torrens M. Dual diagnosis screening interview to identify psychiatric comorbidity in substance users: development and validation of a brief instrument. Eur Addict Res. 2014;20(1):41–8.

    Article  PubMed  Google Scholar 

  88. McDonell MG, Comtois KA, Voss WD, Morgan AH, Ries RK. Global appraisal of individual needs short screener (GSS): psychometric properties and performance as a screening measure in adolescents. Am J Drug Alcohol Abuse. 2009;35(3):157–60.

    Article  PubMed  Google Scholar 

  89. Martinez-Raga J, Szerman N, Knecht C, de Alvaro R. Attention deficit hyperactivity disorder and dual disorders. Educational needs for an underdiagnosed condition. Int J Adolesc Med Health. 2013;25(3):231–43.

    Article  PubMed  Google Scholar 

  90. Roberts BM, Maybery D. Dual diagnosis discourse in Victoria Australia: the responsiveness of mental health services. J Dual Diagn. 2014;10(3):139–44.

    Article  PubMed  Google Scholar 

  91. Balhara YP, Lev-Ran S, Martinez-Raga J, Benyamina A, Singh S, Blecha L, et al. State of training, clinical services, and research on dual disorders across France, India, Israel, and Spain. J Dual Diagn. 2016;12(3–4):252–60.

    Article  PubMed  Google Scholar 

  92. Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, et al. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug Alcohol Depend. 2016;158:1–7.

    Article  PubMed  Google Scholar 

  93. Minkoff K. Treating comorbid psychiatric and substance use disorders. Psychiatr Times. 2013;30(4):44.

    Google Scholar 

  94. Hammond CJ. The role of pharmacotherapy in the treatment of adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(4):685–711.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev. 2016;5(5):CD005336.

    Google Scholar 

  96. Chander G, Himelhoch S, Fleishman JA, Hellinger J, Gaist P, Moore RD, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care. 2009;21(5):655–63.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Gallego L, Barreiro P, Lopez-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Rev. 2011;13(3):171–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. WPA Section on Dual Disorders, Hospital General Universitario Gregorio Marañon, Madrid, Spain

    Néstor Szerman

  2. Retiro Mental Health Services, Hospital General Universitario Gregorio Marañon, Madrid, Spain

    Carlos Parro-Torres

  3. WPA Section on Dual Disorders, Hospital Italiano, Buenos Aires, Argentina

    Javier Didia-Attas

  4. Division of Addiction, Department of Psychiatry, University of Calgary, Calgary, AB, Canada

    Nady El-Guebaly

Authors
  1. Néstor Szerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Parro-Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javier Didia-Attas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nady El-Guebaly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos Parro-Torres .

Editor information

Editors and Affiliations

  1. The Medical Centre, Nuneaton, United Kingdom

    Afzal Javed

  2. Division of Neuroscience Medicine, Aristotle University, Division of Neuroscience Medicine, Thessaloniki, Greece

    Kostas N. Fountoulakis

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Szerman, N., Parro-Torres, C., Didia-Attas, J., El-Guebaly, N. (2019). Dual Disorders: Addiction and Other Mental Disorders. Integrating Mental Health. In: Javed, A., Fountoulakis, K. (eds) Advances in Psychiatry. Springer, Cham. https://doi.org/10.1007/978-3-319-70554-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-70554-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-70553-8

  • Online ISBN: 978-3-319-70554-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation